NovavaxNVAX
About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Employees: 1,992
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
180% more capital invested
Capital invested by funds: $379M [Q1] → $1.06B (+$681M) [Q2]
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
84% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 31
20% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 56
13% more funds holding
Funds holding: 197 [Q1] → 223 (+26) [Q2]
3.31% more ownership
Funds ownership: 56.12% [Q1] → 59.43% (+3.31%) [Q2]
46% less call options, than puts
Call options by funds: $119M | Put options by funds: $221M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Jefferies Roger Song 60% 1-year accuracy 6 / 10 met price target | 146%upside $25 | Buy Maintained | 16 Oct 2024 |
B. Riley Securities Mayank Mamtani 48% 1-year accuracy 12 / 25 met price target | 155%upside $26 | Buy Reiterated | 10 Oct 2024 |
Jefferies Roger Song 60% 1-year accuracy 6 / 10 met price target | 205%upside $31 | Buy Maintained | 2 Oct 2024 |
B. Riley Securities Mayank Mamtani 48% 1-year accuracy 12 / 25 met price target | 126%upside $23 | Buy Reiterated | 12 Aug 2024 |
JP Morgan Eric Joseph 68% 1-year accuracy 15 / 22 met price target | 12%downside $9 | Underweight Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 24 articles about NVAX published over the past 30 days